Pharmacoeconomic review report: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)
Ocrelizumab (Ocrevus) is a recombinant humanized monoclonal antibody that selectively targets and depletes CD20-expressing B-cells, which are thought to contribute to the inflammatory and neurodegenerative pathogenesis of multiple sclerosis (MS). Ocrelizumab is indicated for the treatment of adult p...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, 2018
|
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references